IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial February 23, 2026 Read More »
IGC Pharma Unveils PRISM™ AI Platform to Move Alzheimer’s Risk Prediction to Brain-Health Action and Commercial Deployment October 13, 2026 Read More »
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026 September 28, 2026 Read More »
